Aim: Previous data from our laboratory have demonstrated that localized aggressive periodontitis (LAP) patients produce elevated levels of pro-inflammatory cytokines in response to TLR4 and TLR2 ligation compared to unrelated and periodontally healthy controls (HC). The aim of the present work is to evaluate the contribution of TLR-related gene expression and miRNA regulation in LAP disease.

Material And Methods: Peripheral blood mononuclear cells (PBMCs) from LAP and health control (HC) patients were isolated. Gene and miRNA expression involved in TLR signalling pathway and immunopathology were evaluated in unstimulated PBMCs by real-time PCR (RT-PCR).

Results: TICAM-1 (TRIF), FOS, IRAK1, TLR2 and CCL2 genes and the miRNAs miR-9-5p, miR-155-5p and 203a-3p, miR-147a, miR-182-5p and miR-183-5p were significantly up-regulated in LAP compared to HC.

Conclusions: Most of the genes and miRNAs overexpressed here are directly or indirectly related to immune response and inflammation. This profile supports our previous findings that suggests LAP patients have a "hyper-responsive" phenotype upon activation of TLR pathway by periodontal pathogens.

Download full-text PDF

Source
http://dx.doi.org/10.1111/jcpe.13361DOI Listing

Publication Analysis

Top Keywords

localized aggressive
8
aggressive periodontitis
8
lap patients
8
genes mirnas
8
lap
5
dysregulation genes
4
genes micrornas
4
micrornas localized
4
periodontitis aim
4
aim previous
4

Similar Publications

Background And Purpose: It remains unclear whether the lymph-node ratio (LNR) is a relevant factor for the risk of recurrence following neoadjuvant chemotherapy (nCT) with docetaxel, cisplatin, and 5-fluorouracil (DCF), which is a new standard of care for locally advanced esophageal squamous cell carcinoma (ESCC) in Japan. This study aimed to evaluate the clinical utility of LNR as a risk factor for recurrence.

Materials And Methods: We retrospectively analyzed 75 patients who underwent nCT-DCF followed by curative surgery for resectable ESCC.

View Article and Find Full Text PDF

Introduction: Stage IV non-small cell lung carcinoma (NSCLC) with oligometastases is potentially curable by radical treatment. This study aimed to evaluate the efficacy and safety of chemoradiotherapy (CRT) for thoracic disease, including the primary lesion and lymph node metastases, combined with local consolidative therapy (LCT) for oligometastases.

Methods: This was a multicenter Phase II trial for patients with Stage IV NSCLC with oligometastases for whom CRT for thoracic disease was feasible.

View Article and Find Full Text PDF

Efficacy of PDD-guided tumor excision combined with photodynamic therapy in cutaneous squamous cell carcinoma.

Photodiagnosis Photodyn Ther

January 2025

Department of Plastic & Cosmetic Surgery, Daping Hospital, Army Medical University, Chongqing 400042, China. Electronic address:

Background: Cutaneous squamous cell carcinoma (cSCC) is an aggressive tumor with unclear margins. Photodynamic diagnosis (PDD) enables the differentiation of tumor tissue from normal tissue via visible fluorescence. Photodynamic therapy (PDT) is widely used in the treatment of non-melanoma skin tumors.

View Article and Find Full Text PDF

Ramadan fasting in adolescents with epilepsy: Seizure control and behavioral outcome.

Seizure

December 2024

Neurology Department, Kasralainy Faculty of Medicine, Cairo University, Cairo, Egypt. Electronic address:

Data about the effect of Ramadan fasting on seizure control among adolescents with epilepsy (AWE) is scarce. Several psycho-behavioral problems have also been encountered in this teenage group. This study aimed to assess seizure frequency and behavioral outcomes after Ramadan fasting in a sample of AWE METHODS: In this prospective study, AWE who completed fasting during Ramadan 2024 were evaluated regarding the seizure frequency of each type during Shaban (the month immediately preceding Ramadan) and Ramadan.

View Article and Find Full Text PDF

Background: Esophageal cancer (ESC) is an aggressive disease which often presents at an advanced stage. Despite trimodal therapy, 40-50% patients can develop metastatic disease by 18 months. Identification of patients at risk for metastatic spread is challenging with need for improved prognostication.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!